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                                           ABSTRACT 
 
 
      Apoptosis is a process which self-destroys and removes unwanted cells in a body. It takes 
place to maintain a constant cell numbers and to balance the cell proliferation. Additionally 
apoptosis provide a defense mechanism by which damaged and potentially dangerous cells get 
eliminated from the body. Similarly it gets activated when cell has undergone DNA damage and 
as a result of which it induced apoptosis. Control of gene expression is exerted at a number of 
different levels, one of which is the accessibility of genes and their controlling elements to the 
transcriptional machinery. Accessibility is dictated broadly by the degree of chromatin 
compaction, which is influenced in part by polycomb group proteins. EZH2, together with 
SUZ12 and EED, forms the polycomb repressive complex 2 (PRC2), which catalyzes 
trimethylation of histone H3 at lysine 27 (H3K27me3).This study was aimed to defined the 
oncogenic role of EZH2 and Ras signaling components and it role in induction of apoptosis.  The 
study was performed to know the role played by epigenetic modulators 5 Aza 2`deoxycytidine 
(AZA) and Trichostatin A (TSA) on MDA MB-231 cells and the changes takes place       after  
adding these epigenetic modulators.
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                                                      INTRODUCTION 
 
       In an adult human being all kind of cells contain the same genetic material. But 
astonishingly these cells perform different function in different parts of the body.  This fate of 
the cells is decided by the initial expression of their gene and after the fate and position of the 
cells are decided, than their identity is preserved by keeping some genes on and others off. If the 
maintenance mechanism fails, the cells whole functions get change by losing their properties of 
proliferation, differentiation, adhesion or invasion etc. which cause a disease which we all known 
as by the name of cancer [1, 2].Cancer is a disease that cause from the defects in maintaining the 
original cellular memory, causing cells to loss its normal function and react inappropriately. The 
Polycomb Group (PcG) and Trithorax Group (TrxG) have been identified to keep the cellular 
memory and ensures a faithful transmission of information for which gene has to be active or 
repressed from mother to daughter cells [1, 3]. They execute the process through epigenetic 
modification like DNA methylation, histone modification and chromatin remodeling to complete 
their normal function [4, 5]. 
       For maintaining and establishing the original cellular identity, many pathways are involved 
in repressing or activating particular sets of genes. The genes of Polycomb group and trithorax 
group are conserved from Drosophila to mammals and they maintain the same transcription 
memory patterns which are established during the early stages of embryonic life, and are 
continued from one cellular generation to the next. The TrxG and PcG proteins are two 
antagonistic groups which are required for the regulation of genes related to development and 
cell cycle through activation and repression respectively. As chromatin contains the imprints 
underlying the cellular memory and epigenetic inheritance, both multimeric complexes can act 
on their target genes by modulating chromatin structure. In Drosophila and mammals, both TrxG 
and PcG bind to a specialized DNA element, Polycomb/Trithorax Response Elements 
[PREs/TREs] to perform their epigenetic function [6]. 
         By genetic screening, TrxG and PcG were initially identified in Drosophila to establish and 
maintain homeobox (Hox) gene expression patterns [7-9]. But the function of the TrxG and PcG 
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EZH2 
RUBBP4/7 
SUZ 12 
EED 
is not limited to regulate Hox gene expression [10]. Further studies have shown that these 
proteins bind to thousands of chromosomal site in addition to the Hox genes [8, 9]. 
      The PcG proteins comprise of multiprotein complexes, which appear to perform their 
respective functions. Two distinct Polycomb complexes have been characterized by immune 
precipitation, yeast two hybrid and size-fractionation experiments in mammalian system. The 
Polycomb Repressive Complex 1 (PRC1) constitute BMI-1, RING1, HPH1/2/3, and HPC1/2/3 
(Psc, dRING, ph and Pc in Drosophila) proteins [5, 11] and EZH2, EED, SUZ12, RbAp46/48 
and AEBP2 (E(z), Esc, Su(z)12, and RbAp48 in Drosophila) [5, 9, 11] make the Polycomb 
Repressive Complex 2 (PRC2).Polycomb Repressive Complex 2 (PRC2) plays a vital role in the 
chromatin modification by di- and tri-methylation of Lys 27 of Histone H3 (H3K27me2/3) [5, 
12-14]. The high level of H3K27me3 transforms the genes to a silenced state and transcriptional 
repression in higher eukaryotes. 
 
 
 
 
 
 
 
 
 
 
 
                                                   Fig 1: Components of PRC2 
 
COMPONENTS OF PRC2 
      The four core proteins of PRC2 are conserved from Drosophila to humans and it’s weigh 
about 230 KDa [15]. The EED protein which stands for embryonic ectoderm development is a 
human homolog for Esc protein of Drosophila. It is a short protein of 425 amino acids that 
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contain five WD40 repeats, shown to form a β propeller structure [16]. The Suppressor of zeste 
12 (SUZ12) protein is 900 amino acid long and characterized by a C2H2- type zinc finger and a 
carboxy-terminal VEFS domain [17]. The catalytic subunit of PRC2 protein is EZH2 which 
encodes a 760- amino acid protein containing a conserved SET domain that confers histone 
lysine methyl-transferase (HKMT) activity. In addition to the essential role of EED and SUZ12 
in PRC2, histone-binding protein RBBP4 (or RbAp48/46) and the zinc finger protein AEBP2 
bind to PRC2 and optimize its enzymatic activity in vitro [11]. 
 
      Ezh2 activity appears to depend on interaction with both Suz12 and the WD40 domain in 
EED [11, 18]. EED’s WD40 beta propeller, in turn, interacts with H3K27me3 repressive marks. 
This interaction is proposed to promote the allosteric activation of PRC2 methyltransferase 
activity [18]. RbAp48 also contains a WD40 propeller required for interaction with both Suz12 
and the first 10 residues of unmodified Histone H3 peptides. Biochemical studies have shown 
that PRC2 co-purifies with the protein AEBP2 and it has been proposed that this interaction aids 
in targeting of PRC2 to specific DNA sites and enhances its methyltransferase activity [19]. This 
important cofactor is an evolutionarily conserved protein present in two isoforms in humans, an 
adult-specific larger form (51 kDa) and an embryo-specific smaller form (32 kDa), both 
containing three Gli-Krüppel (Cys2-His2)-type zinc fingers [20]. 
 
EZH2 and DNA Methylation 
       
      The polycomb group protein EZH2 directly controls DNA methylation. The essential 
epigenetic systems involved in heritable repression of gene activity are the Polycomb group 
(PcG) proteins [21, 22] and the DNA methylation systems [23, 24]. These two processes are not 
independent but dependent on each other for the repression of gene expression. Through 
chromatin immunoprecipitation technique it was indicated that the binding of DNMTs to several 
EZH2-repressed genes depends on the presence of EZH2 [4]. Furthermore it was revealed 
through bisulphite genomic sequencing that EZH2 is required for DNA methylation of EZH2-
target promoters [4, 25]. Thus EZH2 serves as a recruitment platform for DNA methyltransferase 
(Figure: 2).  
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      The PcG proteins are responsible for de novo DNA methylation in cancers or cancer cell 
lines [26]. Through ChIP analyses, it is revealed that genes having DNA methylation in cancer 
are marked with Polycomb proteins. It’s already known that, repression of many tumor 
suppressors genes are done by de novo DNA methylation, and they are already pre-marked with 
H3K27 tri-methylation, indicating the mechanism by which EZH2 and PRC2 promote the 
progression of cancer. In normal tissues, some tumor suppressors are marked with H3K27 tri-
methylation, but de novo DNA methylation is not reported, therefore it signifies that EZH2 alone 
cannot causes DNA methylation, but several other components are required methylate DNA for 
gene repression. 
 
 
Fig 2: PRC2 is first recruited to DNA resulting in H3K27me3. This mark facilitates recruitment 
of PRC1, DNMT and HDAC. (Source: Aberration of EZH2 in cancer)[27] 
 
EZH2 and Cancer 
 
       Through genome-wide analysis and various DNA methylation analyses, it has been reported 
that PRC2-mediated H3K27me3 as an epigenetic mark pathogenically which involved in cancer 
progression through silencing of tumor suppressor genes [28-31]. The expression and functions 
of EZH2 is altered in cancer cells and its overabundance is correlates with tumor aggressiveness 
and poor prognosis. EZH2 normally doesn’t express in adult cells but it is overexpressed in a 
broad range of hematopoietic and solid human malignancies (Table 1), where its overabundance 
is often associated with poor prognosis. The overexpression of EZH2 was first reported in 
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aggressive and metastatic prostate cancer through gene expression profiling. In breast cancer, 
abnormally high levels of EZH2 are likewise associated with tumor aggressiveness, increased 
risk of metastasis and shorter patient survival. Increased cell proliferation is commonly 
associated with EZH2 overexpression in cancers. Conversely, loss of EZH2 inhibits growth of 
cancer cells. 
 
TABLE 1:- Overexpression of EZH2 and its functions in human cancers. 
TYPE OF CANCER         FUNCTION      REFERENCES 
Prostate Cancer 
     Cellular Transformation 
     Proliferation 
     Invasion and Metastasis 
              [32, 33] 
Breast Cancer                        
      Cellular transformation  
     Proliferation 
     Invasion and metastasis                
              [34, 35] 
Lymphomas       Proliferation               [36] 
Bladder carcinoma                 
      Cellular transformation 
     Proliferation 
              [37] 
Colon cancer       Proliferation               [38] 
Hepatocellular carcinoma       
      Proliferation 
     Invasion and metastasis 
              [39] 
Pancreatic cancer                    
      Proliferation 
     Anti-apoptosis 
                                                   
              [40] 
 
Epigenetic Modulators 
 
    Human cancers result largely from the inappropriate silencing or activation of genes. It is well 
recognized that the expression of a gene can be controlled to some extent by modulating the 
access of the transcriptional machinery by targeting genes through chemical modifications of 
DNA sequences or histones. These modifications are done with the help of cellular enzymes, 
including DNA methyltransferases, histone acetyl transferase (HATs), histone deacetylases 
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(HDACs), histone methyltransferases (HMTs), histone demethylases, and histone kinases. 
Epigenetics enzymes plays an important role during the embryonic development by regulating 
differentiation pathways, and in adults life also they continue to play there role in specific tissues 
by maintaining epigenetic and transcriptional patterns and act as a co-regulator for transcription 
factor. During various cancers, these epigenetic enzymes loss their function and expressed 
abnormally as a result of which the transcriptional processes get altered which lead to the 
silencing of tumor suppressor genes or unchecked cellular growth [41]. 
 
      For the last two decades, it has been tried to identify the drugs that can modulate the 
pathways mediated by epigenetic enzymes. However, till now only a few drugs have shown 
success in clinical trials, and others are toxic due to their unspecific effects on cellular function 
[42-44].To date, there are only a few epigenetic drugs which are approved by the FDA, 
including: 5-azacytidine which is a DNA methyltransferase inhibitor [45]. Another drug known 
as Trichostatin A (TSA), is an antifungal antibiotic having cytostatic and differentiating 
properties in mammalian cell culture, and also a potent and specific inhibitor of histone 
deacetylase (HDAC) activity [46, 47]. 
 
5-aza 2`-deoxycytidine (AZA) 
 
       5-aza 2`-deoxycytidine is an analog of cytosine residue which competes with cytosine for the 
active site of DNA methyltransferase (DNMT) (figure 3). When AZA is present inside a nucleus 
it inhibits DNA methylation which results in the loss of methylation level of specific genes and 
activation of that particular gene. Normally the catalytic mechanism of DNA methyltransferase 
start with a formation of a covalent bond between a cysteine (Cys) residue present in the active 
site of the enzyme and carbon 6 (C6) of cytosine (Cyt) in DNA. This increases the flow of 
electrons to carbon 5 (C5), with a subsequent attack on the methyl group of S-Adosyl 
Methionine(SAM).This led to the abstraction of a proton from C5 followed by β -elimination and 
reformation of the 5 = 6 double bond and release of the enzyme and DNA with a methylated 
Cytosine. Therefore AZA plays its inhibitory role by binding to the active site of DNMT which 
results in the decrease it activity. 5-Aza-2′-deoxycytidine, when get added into the genomic 
DNA in sites that are to be occupied by cytosine during replication, is best known as an inhibitor 
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of DNA methyltransferases (DNMTs—DNMT1, DNMT3A, andDNMT3B) through covalent 
adduct formation with the enzyme [48]. 
 
 
                                                  
 
 
 
 
                                              Fig 3: 5-Aza 2`-deoxycytidine 
Trichostatin A 
       
     Trichostatin A (TSA) is an antifungal antibiotic with cytostatic and differentiating properties 
in mammalian cell culture and is a potent and specific inhibitor of histone deacetylase (HDAC) 
activity (Figure 4).   
                                                            
 
 
 
 
 
 
    
                                                           Fig 4: Trichostatin A 
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                                     REVIEW OF LITERATURE 
 
       In mammals, two main Polycomb group complexes exist - Polycomb repressive complex 1 
(PRC1) and 2 (PRC2). PRC1 compacts chromatin and catalyses the mono-ubiquitylation of 
histone H2A. PRC2 also contributes to chromatin compaction and catalyses the methylation of 
histone H3 at lysine 27. PRC2 is involved in various biological processes, including 
differentiation, maintaining cell identity and proliferation, and stem-cell plasticity [15].JNK-
STAT3-Akt signaling axis to EZH2 phosphorylation to add novel pathway of carcinogenesis 
[49]. Simon and colleagues in  the April 1, 2012, issue of Genes & Development, correlated 
disruption of Ezh2 in mice is sufficient to T-acute lymphoblastic leukemia (T-ALL) development 
and it was shown that a similar mechanism is involved in human T-ALL development [50]. 
EZH2 mediates transcriptional repression through the characteristic methyltransferase activity at 
the chromatin level has certain influence on lymphoma, and suggests a therapeutic window for 
the development of new agents and identification of EZH2based  novel diagnostic markers [51]. 
       
      Ezh2-KI mice develop myeloproliferative disorder, showing excessive myeloid expansion in 
bone marrow and spleen, leukocytosis and splenomegaly. Ezh2 plays critical role in in 
haematologic malignancies by regulating hematopoietic stem cell-specific genes such as Evi-1 
and Ntrk3 that are often aberrantly expressed [52]. EZH2, a novel prognostic biomarker in 
NSCLC promotes progression and invasion of non- small cell lung cancer [53]. EZH2 implicates 
disease progression, at least partly through promoting cell growth, confers tumor aggressiveness. 
Thus it represents an independent adverse prognosticator in patients with NPC [54]. In triple-
negative breast cancer, high enhancer of zeste homolog 2 expression is significantly associated 
with decreased survival [55].Increased expression of EZH2 does not necessarily correlate with 
increased abundance of H3K27me3 always to support the idea that EZH2 can have effects 
beyond epigenetic silencing of target genes in breast cancer [56]. Loss of heterozygosity 
affecting chromosome 7q is common in acute myeloid leukemia and myelodysplastic syndromes 
and this gives the importance of that region in diseased phenotypes and clonal evolution 
involving a homozygous EZH2 mutation [57]. PTEN and MYC exist in homeostatic balance to 
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control normal growth which is disrupted in cancer cells. MYC acts via the PTEN tumor 
suppressor and elicit auto-regulation with genome-wide gene repression by activation of the 
Ezh2 methyltransferase [58]. EZH2 has also role in nasopharyngeal carcinoma as it significantly 
enhanced the proliferation and invasion of nasopharyngeal carcinoma cells in vitro, which might 
be mediated by inducing EMT [59]. AXL receptor kinase expression is found in human gliomas 
with high EZH2 expression and drives glioma invasiveness via transcriptional control of AXL 
receptor kinase independent of histone or DNA methylation [60]. EZH2 is also shown to be 
associated with high grade and basal-like tumors [61]. EZH2 accelerates cancer cell invasion, in 
part, via RKIP(Raf-1 kinase inhibitor protein)inhibition and is involved in  the regulation of 
RKIP transcription which suggests a potential mechanism by which EZH2 promotes tumor 
progression and metastasis [62]. 
 
Mutation, EZH2 and Cancer 
 
 
        Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes 
hyper-trimethylation of histone H3 on lysine 27 (H3K27) [63]. EZH2 mutations appear to be 
critical in T-cell acute lymphoblastic leukemia development. In addition, the discovery of 
frequent mutations in , EZH2, CREBBP, EP300 and MLL2 in B-cell lymphomas suggests that 
epigenetic alterations play a critical role in lymphomagenesis [64]. Recently, four EZH2 single-
nucleotide polymorphisms (SNPs) have been described in colorectal cancer (mCRC). One allelic 
variant (rs3757441 C/C versus C/T or T/T) was significantly associated with shorter progression-
free survival (PFS) and overall survival (OS). At multivariant analysis, the same variant resulted 
an independent predictor of PFS and OS. The C/C variant was associated with significantly 
higher EZH2 expression. An EZH2 SNP may be useful to predict clinical outcome in mCRC 
patients [65]. In another study where eight matched tumor-constitutional DNA pairs from 
patients with sporadic parathyroid adenomas underwent whole-genome capture and high-
throughput sequencing , revealed that one tumor harbored a Y641N mutation of the histone 
methyltransferase EZH2 gene, previously linked to myeloid and lymphoid malignancy 
formation. This implicates a previously unassociated methyltransferase gene  EZH2, in 
endocrine tumorigenesis and therapy [66].A substantial proportion of patients with 
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myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor 
Spliceosomemutations , which are often missense in type. Such mutations are infrequent in other 
lymphomas, which instead display a separate group of novel mutations involving genes whose 
products are believed to affect histone acetylation and methylation and chromatin structure (for 
example, EZH2 and MLL2) [67]. 
 
 
EZH2 IN CANCER THERAPY 
 
     Overexpression of the Polycomb repressive complex2 (PRC2) subunit Enhancer of Zeste 2 
(EZH2) occurs in several malignancies, including prostate cancer, breast cancer, 
medulloblastoma, and glioblastomamultiforme etc. EZH2 also enhances cancer-cell proliferation 
and regulates stem cell maintenance and differentiation. Henceforth, EZH2 targeting via various 
pharmacological interventions may proof beneficial in cancer therapy. Here we discuss some of 
the recent methods of targeting this epigenetic regulator in different cancers. 
 
     Current evidences suggest that EZH2 may also have a role in rhabdoid tumors. Atypical 
teratoid/rhabdoid tumor (ATRT) characterized by absence of the chromatin remodeling protein 
SMARCB1, have an expression profile inversely correlated to the Ezh2 expression. The targeted 
disruption of EZH2 by RNAi or pharmacologic inhibition strongly impairs ATRT cell growth, 
suppresses tumor cell self-renewal, induces apoptosis, and sensitizes these cells to radiation with 
a simultaneous repression of cyclin D1-E2F axis [68]. EZH2 may be a useful biomarker of long-
term metastatic risk in women with familial early-stage breast cancer [69]. The p53/p21 
inactivation combined with high expression of mitotic cyclins and EZH2 predispose to mitotic 
entry during S-phase with cells reliant on WEE1, a serine/threonine kinase, to prevent premature 
cyclin-dependent kinase (CDK) 1 activation. These features are characteristic of aggressive 
breast, and other, cancers for which WEE1 inhibitor combinations are a promising targeted 
therapy [70]. 
 
       EZH2 is now rising as a potential therapeutic target especially in high-risk tumors. EZH2 is 
highly expressed in medulloblastoma and can be correlated with genomic gain of chromosome 7. 
3-deazaneplanocin(a potent EZH2 inhibitor) treatment or RNAi mediated inhibition of EZH2  
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can suppress medulloblastoma cell growth partially via inducing apoptosis and diminishing 
sphere forming ability of tumor cells  in culture which strongly represses the known oncogenic 
transformation to neural stem cells [71]. A number of HMTs (Histone methyl Transferases) have 
been implicated in tumorigenesis and progression of multiple malignancies. Potent inhibitors and 
ligands for some of these proteins using many high-throughput screening methods have been 
identified that includes WDR5 and EED, components of MLL and EZH2 methyltransferase 
complexes [72]. Again HMTases, EZH2 and MMSET, are established to have epigenetic links to 
oncogenesis by working in coordination. EZH2 function upstream of MMSET by mediating 
H3K36 dimethylation that is associated with active transcription. With an abundant miRNA 
network this EZH2-MMSET HMTase axis coordinately plays many functions as a regulator of 
transcriptional repression, activation, and oncogenesis thus can be  signified as an attractive 
therapeutic target in cancer [73]. 
 
     Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of 
Zeste homolog-2 (EZH2). The inhibitor of EZH2, 3-deazaneplanocin A (DZNeP; 5 mumol/L, 
72-hour exposure) modulate EZH2 expression and H3K27me3 formation and significantly 
triggered the anti-proliferative activity of gemcitabine. The drug combination reduced the 
population of cells in G(2)-M phase and significantly amplified apoptosis compared with 
gemcitabine alone. DZNeP /gemcitabine combination reduced cell migration and associated with 
increased E-cadherin expression. Furthermore, DZNeP and DZNeP/gemcitabine combination 
effectively reduced the volume of PDAC spheroids growing in CSC-selective medium and 
reduced the CD133+ cells population [74]. Though DZNep (3-deazaneplanocin A) show 
promising anticancer activity, the specific genetic determinants underlying DZNep 
responsiveness in cancer cells remain largely unknown. TP53 genomic status is critical in 
influencing DZNep response in gastric cancer. Patients with gastric cancer can be stratified based 
on their TP53 genomic status through EZH2 DZNep targeting [75]. Tumor-initiating HCC cells 
are highly dependent on EZH2 for their tumorigenic activity. A short-hairpin RNA and S-
adenosylhomocysteine hydrolase inhibitor  like 3-deazaneplanocin A (DZNep)  induced 
pharmacological interference with EZH2  might be a promising therapeutic approach to target 
tumor-initiating HCC cells [76]. PRC2 targets are specifically silenced in some metastatic 
cancers, and some of them can inhibit angiogenesis. At inhibitory concentration, DZNeP is 
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harmless for non-transformed cells [77].   In another experiment treatment with DZNep depleted 
EZH2, SUZ12, and 3MeK27H3 in the cultured humanMantle cell lymphoma (MCL) cells [78]. 
Inhibition of EZH2 with siRNA and DZNep treatment cancer cell were incurred to apoptosis in 
addition reduced profoundly in colony-forming efficiency and induction of some squamous 
differentiation genes in HNSCC. Furthermore in two different xenograft models DZNep 
attenuated tumor growth, caused intra tumor inhibition of EZH2, and induction of differentiation 
genes in situ[79].  
 
      In Malignant Pleural Mesothelioma Cancer (MPM) overexpression of EZH2 is reported with 
decreased levels of miR-101 and miR-26a. Global H3K27Me3 levels were decrease by the 
knockdown of EZH2 or EED, or DZNep treatment, thereby significantly inhibited proliferation, 
migration, clonogenicity, and tumorigenicity of MPM cells. Common as well as differential gene 
expression profiles were observed following knockdown of PRC-2 members including EZH2 or 
DZNep treatment [80]. In leukemic cells DZNep can reactivate target genes CDKN1A and 
FBXO32 which are silenced by distinct epigenetic mechanisms leading to a loss of the 
proliferative potential [81].  
 
       Babbio et al. proposed that UHRF1 expression was negatively correlated with several 
tumour suppressor genes and positively with the histone methyltransferase (HMT) EZH2 both in 
prostate tumours and cell lines. Prostate cancer cells reduced proliferation, clonogenic capability 
and anchorage-independent growth by knockdown UHRF1.  UHRF1, along with Suv39H1 and 
DNA methyltransferases, contributes to epigenetic gene silencing in prostate tumours. These 
represents a parallel and convergent pathway to the H3K27 methylation catalyzed by EZH2 to 
significantly amplify inactivation of tumour suppressor genes [82]. HIC1 (hypermethylated in 
cancer 1) is a tumor suppressor gene epigenetically silenced or deleted in many human cancers 
and is involved in regulatory loops modulating p53- and E2F1-dependent cell survival, growth 
control, and stress responses. HIC1 as the first transcription factor in mammals able to recruit 
PRC2 to some target promoters through its interaction with Polycomb-like proteins  EZH2, EED, 
and Suz12 and can suitably be targeted in different cancers [83]. Studies identify several 
potential therapeutic targets for SCLCs, including PARP1 and EZH2 and hypothesize that PARP 
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and EZH2 inhibition, together with chemotherapy or other agents which demands further 
investigation [84]. 
      In an animal model the functional synergy in prostate cancers resulting from activation of the 
androgen receptor, Kras, and Akt, drives three of the most frequently activated oncogenic 
signaling pathways in prostate cancer. The synchronization of androgen receptor and Kras 
signaling could elevate EZH2 expression and expand prostate cancer progenitor cells in vivo. So 
a combine targeting of EZH2 with these signaling factors can be beneficial [85]. Let-7a, a 
microRNA precursor is frequently downregulated in various types of human cancer including 
nasopharyngeal carcinoma. Let-7a directly targets Enhancer of zeste homolog 2 (EZH2) in 
human nasopharyngeal carcinoma cells and thus attenuates nasopharyngeal carcinoma cell 
growth, inhibits cell proliferation and induces cell apoptosis. These outcomes suggest that let-7a 
and EZH2 may be potential therapeutic targets for nasopharyngeal carcinoma [86].  
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                                                    OBJECTIVES 
 
1. To analyses the effect of epigenetic modulator 5-Aza 2`-deoxycytidine (AZA) 
and Trichostatin A (TSA) on breast cancer cell line MDA MB_231. 
 
2. To analyses the transcriptional level of EZH2, K-RAS and ELK-1after the 
treatment of epigenetic modulator AZA and TSA and to analyses its apoptotic 
induction. 
 
3. To analyses the morphological changes in MBA MB-231 cell after the 
treatment of AZA and TSA. 
 
4. To analyses apoptotic induction by chromatin condensation. 
 
5. To analyses the migration property, autophagosome formation and DNA 
damage of MDAMB-231 treated with AZA and TSA. 
 
 
 
 
 
 
 
 
 
                          
Materials and Methods   2013 
 
15  
 
 
                                    
                                  MATERIALS AND METHODS 
 
1. Cell lines and culture 
     We obtained the MDA MB-231 cell line from the National Centre for Cell Science (NCCS), 
Pune, India. The cells are known to be of epithelial breast adenocarcinoma origin and are triple 
negative. These were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% 
fetal bovine serum, 2 mM L-glutamine, and 100 units/ml penicillin-streptomycin sulfate 
(Invitrogen). A treatment was carried out with 5-Aza 2`-deoxycytidine (AZA) and Trichostatin A 
(TSA), all purchased from Sigma and added to the regular growth media under sterile conditions 
for 3 days. The media was changed every 24 hour during treatments. All cells were cultured at a 
density of 1.0 × 10
5
 viable cells/plate in 6 well culture plates. 
 
 
2. MTT Assay 
      To determine the proliferative activity, MDA MB-231 cells were seeded in two 96-well 
plates at a density (5000-40,000 cells or 10
6
 cells) based on the doubling time, with 200 μl 
growth media (10% FBS) and incubate for 24 hrs in incubator with 5% CO2 concentration at 
37
o
C. Cell seeding must be uniform in order to obtain a dose response effect of the drug. The 
drug of interests 5-Aza 2`-deoxycytidine (AZA) and Trichostatin A (TSA) were diluted at 10 
different concentrations in the growth media. In parallel the cells with the solvent control was 
also treated to assess its effect on cells. After 24 hours existing media was removed and replaced 
with media with various concentration of drugs and was incubated for 24 or 48 hours at 37
o
 C. 
To detect the cell viability MTT working solution was prepared by diluting the stock solution 
(stock 5mg/ml PBS, PH 7.2) in growth medium without FBS to the final concentration of 
0.8mg/ml.100 μl of MTT working solution was added to each well and incubated for 4 hours in 
CO2 incubator. After incubation, the media was removed carefully without disturbing formazan 
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precipitate and dissolved in 100 μl of 100% DMSO. An incubation of 15 minutes was carried out 
in dark and the colorimetric estimation of formazan product was performed at 570nm in a micro 
plate reader. The data was plotted against drug concentration and non-linear regression curve 
fitting was performed using graph pad prism software to calculate the optimal growth inhibitory 
concentration (LC50) of the drugs. 
 
3. Isolation of Total Cellular RNA 
 
      The total cellular RNA was extracted using TRI reagent (Sigma), following the 
manufacturer's instructions. On the culture dish 1 ml of the TRI Reagent per 10 cm
2
 of glass 
culture plate surface area was added. After addition of the reagent, the cell lysate was passed 
several times through a pipette to form a homogenous lysate. TRI Reagent is not compatible with 
plastic culture plates. To ensure complete dissociation of nucleoprotein complexes, samples were 
allowed to stand for 5 minutes at room temperature. 0.1 ml of 1-bromo-3-chloropropane or 0.2 
ml of chloroform were added for per ml of TRI Reagent used. Samples were covered tightly, 
shaken vigorously for 15 seconds, and were allowed to stand for 2–15 minutes at room 
temperature. The resulting mixture was centrifuged at 12,000 g for 15 minutes at 2–8 °C. 
Centrifugation separates the mixture into 3 phases: a red organic phase (containing protein), an 
interphase (containing DNA), and a colorless upper aqueous phase (containing RNA).The 
aqueous phase was transferred to a fresh tube and0.5 ml of isopropanol was added per ml of TRI 
Reagent used in Sample Preparation, step 1 and mixed. The sample was allowed to stand for 5–
10 minutes at room temperature and centrifuged at 12,000 ´ g for 10 minutes at 2–8 °C. The 
RNA precipitate formed a pellet on the side and bottom of the tube. The supernatant was 
removed and RNA pellets were washed by adding a minimum of 1 ml of 75% ethanol per 1 ml 
of TRI Reagent used in Sample Preparation. The sample was vortexed and then centrifuged 
at 7,500 ´ g for 5 minutes at 2–8 °C. The RNA pellets were briefly dried for 5–10 minutes by air 
drying.  An appropriate volume of nuclease free water was added and mixed by repeated tapping 
at 25 °C for 10–15 minutes. 
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4. Quantification of the total cellular RNA 
       Final preparation of RNA was analyzed using a nano-drop UV spectrophotometric analyzer. 
It was likely that a standard preparation of RNA should have a 260/280 ratio of 1.7 and a 
260/230 ratio of <1.65 which indicates the preparation to be free from proteins and oligo-
peptides contamination. Ethidium bromide (EtBr) staining of RNA in agarose gels visualizes two 
predominant bands of small (2 kb) and large (5 kb) ribosomal RNA, low molecular mass (0.1–
0.3 kb) RNA, and discrete bands of high molecular mass (7–15 kb) RNA. 
 
5. cDNA Synthesis and Evaluation 
       In a 1.5 ml tube 5 µl of Deionized RNAse free water, 1 µl of T18- oligo (1 µg), 6 µl of 
dNTPs (10mM), 6 µl of Total RNA (3 µg) were added to make a total volume of  18 µl . The 
tube with the contents was incubated at 65°C for 3 minutes. The tube was snap cooled on ice and 
6 µl of  Reverse Transcriptase buffer (5X ) ,3 µl  of DTT, 1 µl  of Reverse Transcriptase, 1 µl  of 
RNase inhibitor  and 1 µl  of RNase free water the following  added to make  a  total volume of 
the reaction mix 12 µl .The tube was then snap spinned  and incubated at 45 °C for 45 
minutes. Again an incubation at 90 °C for 5 minutes followed up. After incubation a snap spin 
was carried out and 30 µl of deionized water was added. The cDNA prepared can now be used 
immediately or can be stored at -30 °C.  The synthesized cDNA was evaluated by performing 
PCR for one of the house keeping genes such as β-actin. PCR reaction mix was prepared with 
5.0 µl of 10X Taq polymerase buffer, 2.5 µl of 10mM dNTP mix, 1.5 µl of 1.5 mM MgCl2, 2.0 
µl of Oligo (mActin- Forward) 10 µM, 2.0 µl of Oligo (mActin- Reverse) 10 µM, 1.0 µl   of Taq 
DNA polymerase and 26.0 µl of deionised water to make a total volume of 40.0 µl. Two aliquots 
of 20 µl of PCR mix was transferred into 2 PCR tubes. 5 µl of cDNA was added in one tube and 
5 µl deionized water was added in another. The tubes were snap spinned to collect the contents 
in the bottom of the tubes and were subject to PCR with the following cycling conditions of ; 92° 
C for 3 minutes, 30 cycles of 92 °C 30 sec, 50 °C for 30 sec, 72 °C for 30 sec, 72 °C for 5 
minutes and  4 °C for forever. The contents were loaded in 1.5% agarose gel and electrophoresed 
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along with a molecular weight marker. The gel was visualized under UV light and results were 
documented in a gel documentation system. 
6. RT-PCR Analysis 
   We used total RNA (2 μg) isolated from the cancerous cell lines for reverse transcription and 
amplification. The primers used for RT-PCR were designed so that there is an intron between the 
amplified regions to recognize any DNA contamination. We used four sets of primers to amplify 
EZH2, K-Ras, Elk-1 and β-actin genes having sequence as detailed in Table no.2 for each RNA 
sample. The PCR were carried out using standard protocols and the DNA was amplified under 
the following conditions: 95 °C for 3 min, 30 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C 
for 30 s, and the final extension of 72 °C for 5 min. We then analyzed the PCR products on a 1% 
agarose gel. 
Table. 2 Primers used for RT-PCR Analysis 
Serial 
No. 
Primer Name Sequence Scale(uMol) Purification Length 
1    EZH2 Forward primer 5‘TCAAAACCGCTTTCCTGG3’ 0.025 DST 18 
2 EZH2 Reverse  primer 5’TGTCCCAATGGTCAGCA3’ 0.025 DST 17 
3 K-Ras Forward  primer 5'ACTGGGGAGGGCTTTCTTTG3' 0.025 DST 20 
4 K-Ras Reverse  primer 5'GGCATCATCAACACCCTGTCT3' 0.025 DST 21 
5 Elk-1 Forward  primer 5'CACTTCTGGAGCACCCTGAGTC3' 0.025 DST 22 
6 Elk-1 Reverse  primer 5'AGAGGCCATCCACGCTGATA3' 0.025 DST 20 
 
7. Scanning Electron Microscopy (SEM) Analysis 
Cells on attaining 70% confluence on 0.2% gelatin precoated 10-mm coverslips in 35-mm petri 
dishes were cultured. Dishes without treatment were used as controls and were kept for the same 
period of induction using suitable growth media. After 24 and 48 hours of drug treatment with 5-
Aza 2`-deoxycytidine (AZA) and Trichostatin A (TSA), the dishes containing the coverslips with cells 
were used for SEM analysis. In preliminary experiments, differentiated adipocytes were 
detached and lipid was extracted by normal fixation and dehydration procedures used for SEM 
Materials and Methods   2013 
 
19  
 
.Treatment medium from the dishes was decanted and the cells were fixed with freshly prepared 
2.5% glutaraldehyde in DPBS at 4 °C for 3 h. The dishes with fixed cells were washed twice 
with DPBS and dehydrated with methanol. It was also found that the fixed cells could be stored 
in DPBS at 4 °C for a maximum of 1 week and dehydrated when necessary. Stored dishes were 
brought to room temperature and again washed once with DPBS. Coverslips with dishes were 
then dried in vacuum-assisted desiccators overnight and then stored at room temperature till 
SEM analysis was carried out. The surface of the coverslip was sputter-coated in a vacuum with 
an electrically conductive 5 nm thick layer of Platinum Precession Etching Coating system. SEM 
images were then recorded with a scanning electron microscope at a lower voltage (20 kV) and 
low vacuum mode with a tilt of 30°. 
 
8. Cell migration assay (Scratch assay) 
 
60-mm dishes were coated with proper ECM substrates for the cell type to be studied by 
incubating the dishes overnight at 4 °C or for 2 hours at 37 °C without rotation or shaking. The 
unbound ECM substrate was removed and dishes were blocked and coated with 3 ml of 2 mg ml-
1 bovine serum albumin for 1 hour at 37°C. Then the dishes were once washed with PBS and 
refilled with 3–5 ml of media before plating the cells. For the particular cell type used, the 
appropriate amount of serum in the medium during the in vitro scratch assay is required to be 
determined. It is always recommended to use a lower percentage of serum than that used in the 
growth media to minimize cell proliferation, but just sufficient to prevent apoptosis and/or cell 
detachment. Sub-confluent growing cells were re-suspended in a tissue culture dish by washing 
cells twice with PBS, adding versene containing trypsin, and then mixing cells with medium 
containing serum. The solution was gently pipetted and the dish was rocked to disperse the cells 
equally. An aliquot from the cell suspension was taken and the cell count was determined using a 
hemocytometer. Cells were plated onto the prepared 60-mm dish to create a confluent monolayer 
and incubated properly for approximately 6 hr. at 37°C, allowing cells to adhere and spread on 
the substrate completely. The required number of cells for a confluent monolayer depends on 
both the particular cell type and the size of dishes and need to be adjusted appropriately. The cell 
monolayer was scraped in a straight line to create a ‘‘scratch’’ with a p200 pipet tip.  
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       The debris was removed and the edge of the scratch was smoothed by washing the cells once 
with 1 ml of the growth medium and then replaced with 5 ml of medium specific for the in vitro 
scratch assay. To obtain the same field during the image acquisition markings were created to be 
used as reference points close to the scratch. The reference points can be made by etching the 
dish lightly with a razor blade on the outer bottom of the dish or with an ultrafine tip marker. 
After the reference points were made, the dish was placed under a phase-contrast microscope, 
and reference mark was left outside the capture image field but within the eye-piece field of 
view. The first image of the scratch was taken. The dish was placed in a tissue culture incubator 
at 37°C for 8–18 hours. After the incubation dish was placed under a phase-contrast microscope, 
the reference point was matched; the photographed region was aligned to acquire a second 
image. 
 
9. Analysis of chromatin condensation 
 
     After treatment with drugs, the cells were stained with Hoechst 33342 stain (1 mg/ml) and 
incubated for 10 min at 37°C and images were taken under UV filter using Epi-fluorescent 
Microscope (Nikon TE 2000E). Condensed nucleus was counted against total number of nucleus 
in the field, and the percentages of apoptotic nuclei were analyzed. 
 
10. Cytochemical staining for visualizing autophagosomes 
     An optimal number of cells were seeded based on doubling time in a 96 well plate and kept 
for 24 hours in incubator with 5% CO2 at 37°C.  After the incubation period, the cells were 
challenged with the suspected autophagy modulating factor for 12 hours. Then after incubation, 
the existing media was removed and 100µl of fresh media containing 1µg/ml of acridine orange 
was added. The cells were incubated for 15min at normal culture conditions. The media was 
discarded and washed with PBS and fresh media was added to the cells. The cells were analyzed 
under a fluorescent microscope using blue filter (495nm) to view the green fluorescence (510-
530nm) from free Acridine Orange and red fluorescence (> 650nm) from acidic vesicles 
(autophagosomes).  
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11. Comet assay to measure the DNA damage 
 
       To water baths were equilibrated at 40 °C and ∼100 °C respectively. Than 1% low-gelling-
temperature agarose was prepared by mixing powdered agarose with distilled water in a glass 
beaker or bottle. The bottle was placed in the 100 °C water bath for several minutes and was 
transferred into a 40 °C water bath. Agarose-precoated slides were prepared by dipping the slides 
into molten 1% agarose and wiping one side clean. It is best to work in a low-humidity 
environment to ensure agarose adhesion. Agarose was allowed to air-dry to a thin film. Slides 
can be prepared ahead of time and stored with desiccant. A single-cell suspension was prepared 
using enzyme disaggregation or mechanical dissociation. The cells were kept in ice-cold medium 
or phosphate-buffered saline to minimize cell aggregation and inhibit DNA repair. Using a 
hemocytometer or particle counter, cell density was adjusted to about 2 × 104 cells/ml in 
phosphate-buffered saline lacking divalent cations. Slides were labeled on frosted end using a 
pencil. 0.4 ml of cells into a 5 ml plastic disposable tube.1.2 ml 1% low-gelling-temperature 
agarose at was added at 40 °C.1.2 ml of cell suspension onto the agarose-covered surface of a 
pre-coated slide was mixed by vigorous pipetting. Agarose was allowed to be gel for about 2 
min. After agarose has gelled, slides were submerged in a covered dish containing A1 lysis 
solution. Samples were lysed overnight (18−20 h) at 4 °C in the dark. After overnight lysis, 
slides were removed carefully and submerge in A2 rinse solution for 20 min at room temperature 
(18−25 °C). The process was repeated two times to ensure removal of salt and detergent. Care 
was taken for not allowing DNA to renature even briefly (i.e., by lowering pH below 12.3) until 
after electrophoresis, as this will result in DNA tangling and reduced migration. After these three 
rinses, slides were submerged in fresh A2 solution in an electrophoresis chamber. The chamber 
was filled with a consistent volume of buffer that is about 1–2 mm above the top of the agarose. 
It was ensured that the chamber is level using a bubble leveling device. Electrophoresis was 
conducted in solution A2 for 25 min at a voltage of 0.6 V/cm. The current was about 40 mA 
using 20 V. The distance in centimeters was measured between the negative and positive 
electrodes in the electrophoresis chamber. Slides were removed from electrophoresis chamber 
and were rinsed and neutralized in 400 ml of distilled water. Slides were placed in staining 
solution containing 2.5 μg/ml of propidium iodide in distilled water for 20 min. Finally the slides 
were rinsed with 400 ml distilled water to remove excess stain. Analysis of cells was done by 
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examining at least 50 comet images from each slide. Analyzing doublets or comets at slide edges 
should be avoided. 
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                                                   RESULTS AND DISCUSSION 
 
1. Cell viability assay by MTT Method 
 
      MDA MB -231 cell viability was determined by MTT Assay. Both the AZA and TSA 
treatment showed decrease in cell viability but at lower concentration of TSA treatment showed 
higher decrease in cell viability. 
 
 
            Fig 5. Graphical analysis of cell viability after AZA and TSA treatment 
2. Isolation of Total Cellular RNA by Trizol Method 
     The total cellular RNA isolated was isolated following the manufacturer’s  instructions by 
Tri-reagent (Sigma).The isolation of the RNA was carried out from the cultured cells of the 
wells of the six well plates from two wells in a time dependent manner of 24hour  and 48 hours. 
The isolation was almost pure and in good yield as the reading in Nano drop spectrophotometer 
showed the 260/280 absorption ratio above 1.7 and the 260/230 absorption ratio above 1.65 for 
all the samples quantified.  
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3. cDNA Synthesis and RT-PCR  
       Previous studies and the RT-PCR data confirmed that RAS, ELK-1 and EZH 2 were up 
regulated in breast cancer cell line MDA-MB 231. A time dependent treatment with both AZA 
and TSA for 24hours showed down regulation of these components. 
 
 
Fig 6. Graphical representation of RT-PCR results for expression level of K-Ras, Elk-1 and EZH2 
after AZA and TSA treatment 
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4. Study of change in cellular morphology by Scanning Electron Microscopy 
       After treatment of the MDA MB-231 cells with AZA and TSA in a time dependent manner 
for 24 and 48 hours the change in the cellular morphology was observed by a Scanning Electron 
Microscope. The images suggested that there was a change in the normal cellular morphology of 
MDA MB 231 cells as they started to attain a round shape suggesting an induction of a 
mechanism like apoptosis.  
 
 
     
 
 
 
 
 
 
 
 
 
 
   Fig 7.  SEM images showing changes in cellular morphology after AZA and TSA treatment 
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5. Cell migration study by Scratch assay 
 
        For the study of migratory property of the MDA MB-231 cells after AZA and TSA 
treatment for 0hr, 24hr, 48hr in a time dependent manner the scratch assay was performed .The 
results showed that there was more migration of cells towards the scratched area in AZA treated 
cells as compared to the TSA treated in comparison with the untreated plates taken as control in 
a time dependent manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Control                                                AZA                                                 TSA 
 Fig 8.  Microscopic images showing changes in the migratory property of MDA MB-231 cells after 
AZA and TSA treatment  
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6. Analysis of chromatin condensation by Hoechst 33342 stain 
      After treatment with AZA and TSA for 24-48hr in a time dependent manner the MDA-MB-
231 cells were stained with Hoechst 33342 stain and analyzed for the chromatin 
condensation. The results indicated that there was formation of more condensed structures after 
treatment with AZA and TSA in a time dependent manner. 
 
 
 
 
 
 
 
 
 
   
Fig 9. Fluorescence microscopic condensed chromatin images showing after AZA and        
TSA treatment 
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7.  Cytochemical staining for detecting autophagosomes 
       The MDA MB-231 cells after the formation of the treatment with AZA and TSA for 24-48 
hr. in a time dependent manner were analyzed for the formation of autophagosomes. The AZA 
treated cells showed greater frequency in the formation of autophagosomes after a treatment of 
48 hours. But the TSA treatment was found less efficient in forming the autophagic vesicles. 
 
 
 
 
 
 
 
 
 
 
 
               Control                                                AZA                                                 TSA 
Fig 10.  Fluorescence microscopic images showing formation of autophagosomes after AZA 
and TSA treatment 
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8. DNA damage measured by Comet Assay 
       MDA MB-231 cells in culture after treatment with AZA and TSA for 24-48 hr. in a time 
dependent manner were analyzed for the amount of DNA damage by the comet assay. The 
results showed significant amount of DNA damage in TSA treatment as compared to AZA and 
the untreated control cells. The characteristic comet tail length suggested the amount of DNA 
damaged. In TSA treatment the cells were seen to be having a more dispersed tail as compared to 
the tails of the AZA treated cells and the control untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
             Control                                                 AZA                                                  TSA 
        Fig 11.  Fluorescence microscopic images showing DNA damage after AZA and TSA treatment 
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                                                          CONCLUSION 
 
Apoptosis is a process which is regulated so carefully so that individual cells in a body get it 
ultimate need. It takes place to maintain a constant cell numbers and to balance the cell 
proliferation. Additionally apoptosis provide a defense mechanism by which damaged and 
potentially dangerous cells get eliminated from the body. Similarly it gets activated when cell 
has undergone DNA damage and as a result of which it induced apoptosis. RAS is one of the 
most frequently mutated oncogenes in human cancer. Oncogenic mutations in RAS lead to 
deregulation of several effecter pathways that control cell proliferation, survival, and migration, 
and thus promote malignant transformation. The best-characterized RAS effecter pathway is the 
MEK-ERK cascade. It has seen that downregulation of K-Ras and its downstream component 
Elk-1 has the same effect on EZH2 transcriptional level by treating the cells with AZA and TSA. 
Therefore it has revealed that apoptotic induction of breast cancer cell line MDA MB_231 is 
independent of EZH2, K-Ras and Elk-1. The MTT assay showed that TSA has a higher effect 
than AZA and chromatin condensation showed that TSA treated cells had a greater amount of 
condensed chromatin than AZA treated cells. The comet assay and condensation of chromatin 
has revealed that the cells are undergoing apoptotic death but it has no role with EZH2, K-Ras  
and Elk-1. 
                                                                       References   2013 
 
31  
 
                                                 REFERENCES 
1. Jacobs, J.J. and M. van Lohuizen, Polycomb repression: from cellular memory to cellular 
proliferation and cancer. Biochim Biophys Acta, 2002. 1602(2): p. 151-61. 
2. Francis, N.J., et al., Reconstitution of a functional core polycomb repressive complex. Mol Cell, 
2001. 8(3): p. 545-56. 
3. Bantignies, F. and G. Cavalli, Cellular memory and dynamic regulation of polycomb group 
proteins. Curr Opin Cell Biol, 2006. 18(3): p. 275-83. 
4. Vire, E., et al., The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 
2006. 439(7078): p. 871-4. 
5. Cao, R., et al., Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 
2002. 298(5595): p. 1039-43. 
6. Simon, J., et al., Elements of the Drosophila bithorax complex that mediate repression by 
Polycomb group products. Dev Biol, 1993. 158(1): p. 131-44. 
7. Beuchle, D., G. Struhl, and J. Muller, Polycomb group proteins and heritable silencing of 
Drosophila Hox genes. Development, 2001. 128(6): p. 993-1004. 
8. Ringrose, L. and R. Paro, Epigenetic regulation of cellular memory by the Polycomb and Trithorax 
group proteins. Annu Rev Genet, 2004. 38: p. 413-43. 
9. Schuettengruber, B., et al., Genome regulation by polycomb and trithorax proteins. Cell, 2007. 
128(4): p. 735-45. 
10. Wang, J., et al., The mouse PcG gene eed is required for Hox gene repression and extraembryonic 
development. Mamm Genome, 2002. 13(9): p. 493-503. 
11. Cao, R. and Y. Zhang, SUZ12 is required for both the histone methyltransferase activity and the 
silencing function of the EED-EZH2 complex. Mol Cell, 2004. 15(1): p. 57-67. 
12. Czermin, B., et al., Drosophila enhancer of Zeste/ESC complexes have a histone H3 
methyltransferase activity that marks chromosomal Polycomb sites. Cell, 2002. 111(2): p. 185-
96. 
13. Muller, J., et al., Histone methyltransferase activity of a Drosophila Polycomb group repressor 
complex. Cell, 2002. 111(2): p. 197-208. 
14. Kirmizis, A., et al., Silencing of human polycomb target genes is associated with methylation of 
histone H3 Lys 27. Genes Dev, 2004. 18(13): p. 1592-605. 
15. Margueron, R. and D. Reinberg, The Polycomb complex PRC2 and its mark in life. Nature, 2011. 
469(7330): p. 343-9. 
16. Moore, H.M., et al., EZH2 inhibition decreases p38 signaling and suppresses breast cancer 
motility and metastasis. Breast Cancer Res Treat, 2013. 138(3): p. 741-52. 
17. Grzenda, A., et al., Functional characterization of EZH2beta reveals the increased complexity of 
EZH2 isoforms involved in the regulation of mammalian gene expression. Epigenetics Chromatin, 
2013. 6(1): p. 3. 
18. Xu, C., et al., Binding of different histone marks differentially regulates the activity and specificity 
of polycomb repressive complex 2 (PRC2). Proc Natl Acad Sci U S A, 2010. 107(45): p. 19266-71. 
19. Zhang, W., et al., Structural plasticity of histones H3-H4 facilitates their allosteric exchange 
between RbAp48 and ASF1. Nat Struct Mol Biol, 2013. 20(1): p. 29-35. 
20. Tanimoto, Y., et al., Prevention of premature fusion of calvarial suture in GLI-Kruppel family 
member 3 (Gli3)-deficient mice by removing one allele of Runt-related transcription factor 2 
(Runx2). J Biol Chem, 2012. 287(25): p. 21429-38. 
21. Lund, A.H. and M. van Lohuizen, Polycomb complexes and silencing mechanisms. Curr Opin Cell 
Biol, 2004. 16(3): p. 239-46. 
                                                                       References   2013 
 
32  
 
22. Levine, S.S., I.F. King, and R.E. Kingston, Division of labor in polycomb group repression. Trends 
Biochem Sci, 2004. 29(9): p. 478-85. 
23. Bird, A., DNA methylation patterns and epigenetic memory. Genes Dev, 2002. 16(1): p. 6-21. 
24. Jaenisch, R. and A. Bird, Epigenetic regulation of gene expression: how the genome integrates 
intrinsic and environmental signals. Nat Genet, 2003. 33 Suppl: p. 245-54. 
25. Patra SK, B.S., Ras regulation of DNA methylation and Cancer. 2008. 
26. Schlesinger, Y., et al., Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes 
for de novo methylation in cancer. Nat Genet, 2007. 39(2): p. 232-6. 
27. Cross, A.C.a.N.C.P., Aberration of EZH2 in cancer. 2011. 
28. Yu, J., et al., Integrative genomics analysis reveals silencing of beta-adrenergic signaling by 
polycomb in prostate cancer. Cancer Cell, 2007. 12(5): p. 419-31. 
29. Kondo, Y., et al., Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of 
promoter DNA methylation. Nat Genet, 2008. 40(6): p. 741-50. 
30. Tan, J., et al., Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene 
repression selectively induces apoptosis in cancer cells. Genes Dev, 2007. 21(9): p. 1050-63. 
31. Fujii, S., et al., Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing 
histone H3 methylation. J Biol Chem, 2008. 283(25): p. 17324-32. 
32. van der Vlag J, O.A., Transcriptional repression mediated by the human polycomb-group protein 
EED involves histone deacetylation. Nat. Genet, 1999: p. 474–8. 
33. Karanikolas BD, F.M., Wu L., Polycomb group protein enhancer of zeste 2 is an oncogene that 
promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol.Cancer Res, 
2009. 7: p. 1456–65. 
34. Kleer CG, C.Q., Varambally S et al, EZH2 is a marker of aggressive breast cancer and promotes 
neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A., 2003. 
35. Collett K, E.G., Arnes J et al., Expression of enhancer of zeste homologue 2 is significantly 
associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. 
2006. 
36. Dukers DF, v.G.J., Giroth C et al., Unique Polycomb gene expression pattern in Hodgkin’s 
Lymphoma and Hodgkin’s Lymphoma-derived cell lines. 2004;. 
37. Weikert S, C.F., Köllermann J et al., Expression levels of the EZH2 polycomb transcriptional 
repressor correlate with aggressiveness and invasive potential of bladder carcinomas. 2005. 
38. Fluge Ø, G.K., Carlsen E et al., Expression of EZH2 and Ki-67 in colorectal cancer and associations 
with treatment response and prognosis. 2009. 
39. Sudo T, U.T., Mimori K et al., Clinicopathological significance of EZH2 mRNA expression in 
patients with hepatocellular carcinoma. 2005. 
40. Ougolkov AV, B.V., Billadeau DD., Regulation of pancreatic tumor cell proliferation and 
chemoresistance by the histone methyltransferase EZH2. 2008. 
41. Jones, P.A. and S.B. Baylin, The epigenomics of cancer. Cell, 2007. 128(4): p. 683-92. 
42. Candelaria, M., et al., A phase II study of epigenetic therapy with hydralazine and magnesium 
valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol, 2007. 
18(9): p. 1529-38. 
43. Ryan, Q.C., et al., Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, 
in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol, 2005. 23(17): 
p. 3912-22. 
44. Khan, O. and N.B. La Thangue, Drug Insight: histone deacetylase inhibitor-based therapies for 
cutaneous T-cell lymphomas. Nat Clin Pract Oncol, 2008. 5(12): p. 714-26. 
                                                                       References   2013 
 
33  
 
45. Kaminskas, E., et al., FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for 
injectable suspension. Oncologist, 2005. 10(3): p. 176-82. 
46. Vigushin, D.M., et al., Trichostatin A is a histone deacetylase inhibitor with potent antitumor 
activity against breast cancer in vivo. Clin Cancer Res, 2001. 7(4): p. 971-6. 
47. Samir K. Patra, A.P., and Rajvir Dahiya, Histone Deacetylase and DNA Methyltransferase in 
Human Prostate Cancer. BBRC, 2001. 
48. Patra SK, B.S., Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2"-deoxycytidine and 
DNA-demethylation. Biochem (Mosc), 2009. 74(6): p. 613–619. 
49. Rojanasakul, Y., Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: a novel pathway 
of carcinogenesis. Cell Cycle, 2013. 12(2): p. 202-3. 
50. Hock, H., A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev, 2012. 26(8): p. 
751-5. 
51. Guo, S.Q. and Y.Z. Zhang, Overexpression of enhancer of zests homolog 2 in lymphoma. Chin 
Med J (Engl), 2012. 125(20): p. 3735-9. 
52. Herrera-Merchan, A., et al., Ectopic expression of the histone methyltransferase Ezh2 in 
haematopoietic stem cells causes myeloproliferative disease. Nat Commun, 2012. 3: p. 623. 
53. Huqun, et al., Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung 
cancer. Cancer, 2012. 118(6): p. 1599-606. 
54. Hwang, C.F., et al., Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: 
an independent poor prognosticator that enhances cell growth. Int J Radiat Oncol Biol Phys, 
2012. 82(2): p. 597-604. 
55. Hussein, Y.R., et al., Clinical and biological relevance of enhancer of zeste homolog 2 in triple-
negative breast cancer. Hum Pathol, 2012. 43(10): p. 1638-44. 
56. Holm, K., et al., Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol 
Oncol, 2012. 6(5): p. 494-506. 
57. Jerez, A., et al., Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic 
pathogenesis. Blood, 2012. 119(25): p. 6109-17. 
58. Kaur, M. and M.D. Cole, MYC acts via the PTEN tumor suppressor to elicit autoregulation and 
genome-wide gene repression by activation of the Ezh2 methyltransferase. Cancer Res, 2013. 
73(2): p. 695-705. 
59. Liang, B.J., et al., [Effects of enhancer of zeste homolog (EZH2) downregulation on the 
proliferation and invasion of nasopharyngeal carcinoma cell and the possible mechanisms]. 
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2012. 47(4): p. 298-304. 
60. Ott, M., et al., Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is 
mediated by AXL receptor kinase. PLoS One, 2012. 7(10): p. e47663. 
61. Pang, J., et al., Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like 
histology and high EZH2 expression. Breast Cancer Res Treat, 2012. 135(1): p. 59-66. 
62. Ren, G., et al., Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression 
of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res, 2012. 72(12): p. 
3091-104. 
63. McCabe, M.T., et al., Mutation of A677 in histone methyltransferase EZH2 in human B-cell 
lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci 
U S A, 2012. 109(8): p. 2989-94. 
64. Chung, Y.R., E. Schatoff, and O. Abdel-Wahab, Epigenetic alterations in hematopoietic 
malignancies. Int J Hematol, 2012. 96(4): p. 413-27. 
65. Fornaro, L., et al., Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter. Clin 
Cancer Res, 2012. 18(16): p. 4473; author reply 4474. 
                                                                       References   2013 
 
34  
 
66. Cromer, M.K., et al., Identification of somatic mutations in parathyroid tumors using whole-
exome sequencing. J Clin Endocrinol Metab, 2012. 97(9): p. E1774-81. 
67. Damm, F., et al., Spliceosome and other novel mutations in chronic lymphocytic leukemia and 
myeloid malignancies. Leukemia, 2012. 26(9): p. 2027-31. 
68. Alimova, I., et al., Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in 
atypical rhabdoid teratoid tumor cells. Neuro Oncol, 2013. 15(2): p. 149-60. 
69. Alford, S.H., et al., Increased risk for distant metastasis in patients with familial early-stage 
breast cancer and high EZH2 expression. Breast Cancer Res Treat, 2012. 132(2): p. 429-37. 
70. Aarts, M., et al., Forced mitotic entry of S-phase cells as a therapeutic strategy induced by 
inhibition of WEE1. Cancer Discov, 2012. 2(6): p. 524-39. 
71. Alimova, I., et al., Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J 
Cancer, 2012. 131(8): p. 1800-9. 
72. Allali-Hassani, A., et al., Fluorescence-based methods for screening writers and readers of histone 
methyl marks. J Biomol Screen, 2012. 17(1): p. 71-84. 
73. Asangani, I.A., et al., Characterization of the EZH2-MMSET histone methyltransferase regulatory 
axis in cancer. Mol Cell, 2013. 49(1): p. 80-93. 
74. Avan, A., et al., Molecular mechanisms involved in the synergistic interaction of the EZH2 
inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther, 
2012. 11(8): p. 1735-46. 
75. Cheng, L.L., et al., TP53 genomic status regulates sensitivity of gastric cancer cells to the histone 
methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res, 2012. 18(15): p. 4201-12. 
76. Chiba, T., et al., 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of 
tumor-initiating hepatocellular carcinoma cells. Int J Cancer, 2012. 130(11): p. 2557-67. 
77. Crea, F., et al., An EZH2 polymorphism is associated with clinical outcome in metastatic 
colorectal cancer patients. Ann Oncol, 2012. 23(5): p. 1207-13. 
78. Fiskus, W., et al., Superior efficacy of a combined epigenetic therapy against human mantle cell 
lymphoma cells. Clin Cancer Res, 2012. 18(22): p. 6227-38. 
79. Gannon, O.M., et al., Dysregulation of the repressive H3K27 trimethylation mark in head and 
neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer 
Res, 2013. 19(2): p. 428-41. 
80. Kemp, C.D., et al., Polycomb repressor complex-2 is a novel target for mesothelioma therapy. 
Clin Cancer Res, 2012. 18(1): p. 77-90. 
81. Momparler, R.L., et al., Synergistic antileukemic action of a combination of inhibitors of DNA 
methylation and histone methylation. Leuk Res, 2012. 36(8): p. 1049-54. 
82. Babbio, F., et al., The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in 
prostate cancer progression. Oncogene, 2012. 31(46): p. 4878-87. 
83. Boulay, G., et al., Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 
(PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) 
proteins. J Biol Chem, 2012. 287(13): p. 10509-24. 
84. Byers, L.A., et al., Proteomic profiling identifies dysregulated pathways in small cell lung cancer 
and novel therapeutic targets including PARP1. Cancer Discov, 2012. 2(9): p. 798-811. 
85. Cai, H., et al., Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression 
and tumor-propagating cells in prostate cancer. Cancer Res, 2012. 72(18): p. 4672-81. 
86. Cai, K., et al., Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in 
nasopharyngeal carcinoma cells. Oncol Rep, 2012. 28(6): p. 2101-6. 
 
                                                                       References   2013 
 
35  
 
 
